{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:44:51Z","timestamp":1785451491548,"version":"3.56.0"},"reference-count":41,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Hematol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is a prevalent hematological malignancy. Resource-constrained settings such as the Middle East are particularly burdened by the increasing trends in MM morbidity and mortality in addition to challenges in the management of MM. It thus becomes necessary to identify and address debatable areas of current practice and gaps in the management of MM in the Middle East. With a special focus on the Lebanese situation, the first-line treatment of the very elderly (&gt;\u200980\u00a0years old) is discussed, in addition to the impact of relapse type (biochemical or clinical relapse) on maintenance therapy, the choice of first relapse therapy in relation to maintenance therapy, and the role of MRD in the MM treatment landscape. The need for realistic management guidelines accounting for local resources and expertise, in addition to the reflection of drug accessibility and cost on clinical practice are recognized.<\/jats:p>","DOI":"10.1007\/s44228-022-00017-3","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T14:04:45Z","timestamp":1661868285000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective"],"prefix":"10.46989","volume":"4","author":[{"given":"Ahmad","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Chamseddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"El-cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Moukadem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"17_CR1","unstructured":"Globocan. Multiple myeloma. 2020. Accessed: Jan. 05, 2021. [Online]. Available: https:\/\/gco.iarc.fr\/today."},{"key":"17_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-021-00198-2","volume":"10","author":"M Keykhaei","year":"2021","unstructured":"Keykhaei M, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990\u20132017. Exp Hematol Oncol. 2021;10:1. https:\/\/doi.org\/10.1186\/s40164-021-00198-2.","journal-title":"Exp Hematol Oncol"},{"key":"17_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12885-021-08280-Y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21:1. https:\/\/doi.org\/10.1186\/S12885-021-08280-Y.","journal-title":"BMC Cancer"},{"key":"17_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133:7. https:\/\/doi.org\/10.1182\/blood-2018-09-825331.","journal-title":"Blood"},{"issue":"9","key":"17_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128.","journal-title":"JAMA Oncol"},{"issue":"4","key":"17_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.hemonc.2017.05.003","volume":"10","author":"A Bazarbachi","year":"2017","unstructured":"Bazarbachi A, et al. Trends in hematopoietic stem cell transplant activity in Lebanon. Hematol Oncol Stem Cell Therapy. 2017;10(4):315\u201320. https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.003.","journal-title":"Hematol Oncol Stem Cell Therapy"},{"key":"17_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.CTARC.2022.100513","volume":"30","author":"M Jalloul","year":"2022","unstructured":"Jalloul M, et al. Multiple myeloma in Lebanon: trend analysis, 10-year projections and comparisons to other countries. Cancer Treat Res Commun. 2022;30: 100513. https:\/\/doi.org\/10.1016\/J.CTARC.2022.100513.","journal-title":"Cancer Treat Res Commun"},{"key":"17_CR8","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.1016\/j.clml.2018.07.138","volume":"18","author":"M Massoud","year":"2018","unstructured":"Massoud M, et al. Survival of multiple myeloma in the lebanese population between January 2005 and December 2017. Clin Lymphoma Myeloma Leuk. 2018;18:S244. https:\/\/doi.org\/10.1016\/j.clml.2018.07.138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"17_CR9","doi-asserted-by":"publisher","first-page":"e20526","DOI":"10.1200\/jco.2020.38.15_suppl.e20526","volume":"38","author":"F Nasr","year":"2020","unstructured":"Nasr F, Nasr L, Ghoche A, Diab S. Lebanese experience in treating multiple myeloma: A multicenter retrospective study. J Clin Oncol. 2020;38(15):e20526\u2013e20526. https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.e20526.","journal-title":"J Clin Oncol"},{"key":"17_CR10","doi-asserted-by":"publisher","first-page":"612696","DOI":"10.3389\/fmed.2021.612696","volume":"8","author":"NM Kaweme","year":"2021","unstructured":"Kaweme NM, Changwe GJ, Zhou F. Approaches and challenges in the management of multiple myeloma in the very old: future treatment prospects. Front Med. 2021;8:612696. https:\/\/doi.org\/10.3389\/fmed.2021.612696.","journal-title":"Front Med"},{"issue":"3","key":"17_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clml.2018.01.005","volume":"18","author":"B Fakhri","year":"2018","unstructured":"Fakhri B, Fiala MA, Tuchman SA, Wildes TM. Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies. Clin Lymphoma, Myeloma Leuk. 2018;18(3):219\u201324. https:\/\/doi.org\/10.1016\/j.clml.2018.01.005.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"5","key":"17_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2014.04.011","volume":"14","author":"N Raje","year":"2014","unstructured":"Raje N, et al. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the managing myeloma continuing educational initiative advisory committee. Clin Lymphoma Myeloma Leukemia. 2014;14(5):356\u201369. https:\/\/doi.org\/10.1016\/j.clml.2014.04.011.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"13","key":"17_CR13","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood. 2015;125(13):2068\u201374. https:\/\/doi.org\/10.1182\/blood-2014-12-615187.","journal-title":"Blood"},{"issue":"1","key":"17_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(09)70284-0.","journal-title":"Lancet Oncol"},{"issue":"22","key":"17_CR15","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/BLOOD.2020009507","volume":"137","author":"A Larocca","year":"2021","unstructured":"Larocca A, et al. Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027\u201336. https:\/\/doi.org\/10.1182\/BLOOD.2020009507.","journal-title":"Blood"},{"issue":"2","key":"17_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell EK, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222\u201330. https:\/\/doi.org\/10.1111\/bjh.15261.","journal-title":"Br J Haematol"},{"issue":"21","key":"17_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.v116.21.619.619","volume":"116","author":"R Niesvizky","year":"2010","unstructured":"Niesvizky R, et al. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. Blood. 2010;116(21):619\u2013619. https:\/\/doi.org\/10.1182\/blood.v116.21.619.619.","journal-title":"Blood"},{"issue":"Suppl 1","key":"17_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/HR.2020.8956","volume":"12","author":"D Derudas","year":"2020","unstructured":"Derudas D, Capraro F, Martinelli G, Cerchione C. How I manage frontline transplant-ineligible multiple myeloma. Hematol Rep. 2020;12(Suppl 1):1\u201315. https:\/\/doi.org\/10.4081\/HR.2020.8956.","journal-title":"Hematol Rep"},{"key":"17_CR19","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up y behalf of the EHA Guidelines Committee * and ESMO Guidelines Committee. 2021;17:22. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014.","DOI":"10.1016\/j.annonc.2020.11.014"},{"issue":"3","key":"17_CR20","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(20)30756-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"17_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587\u2013600. https:\/\/doi.org\/10.1200\/JCO.2013.48.7934.","journal-title":"J Clin Oncol"},{"issue":"9","key":"17_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373. https:\/\/doi.org\/10.1038\/sj.leu.2404284.","journal-title":"Leukemia"},{"issue":"34","key":"17_CR23","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1200\/JCO.20.02060","volume":"38","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020;38(34):4030\u201341. https:\/\/doi.org\/10.1200\/JCO.20.02060.","journal-title":"J Clin Oncol"},{"issue":"4","key":"17_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.25415","volume":"94","author":"R Chakraborty","year":"2019","unstructured":"Chakraborty R, et al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019;94(4):439\u201345. https:\/\/doi.org\/10.1002\/ajh.25415.","journal-title":"Am J Hematol"},{"issue":"3","key":"17_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41375-018-0271-1","volume":"33","author":"S Sidana","year":"2019","unstructured":"Sidana S, et al. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia. 2019;33(3):730\u20138. https:\/\/doi.org\/10.1038\/s41375-018-0271-1.","journal-title":"Leukemia"},{"issue":"8","key":"17_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1634\/theoncologist.2014-0042","volume":"19","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014;19(8):829\u201344. https:\/\/doi.org\/10.1634\/theoncologist.2014-0042.","journal-title":"Oncologist"},{"issue":"7","key":"17_CR27","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","volume":"98","author":"N Tovar","year":"2013","unstructured":"Tovar N, et al. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: Long-term results from a single institution. Haematologica. 2013;98(7):1142\u20136. https:\/\/doi.org\/10.3324\/haematol.2013.084350.","journal-title":"Haematologica"},{"key":"17_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/S41408-019-0205-9","volume":"9","author":"R Al Hamed","year":"2019","unstructured":"Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9:4. https:\/\/doi.org\/10.1038\/S41408-019-0205-9.","journal-title":"Blood Cancer J"},{"issue":"30","key":"17_CR29","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459\u201366. https:\/\/doi.org\/10.1200\/JCO.2014.60.2466.","journal-title":"J Clin Oncol"},{"key":"17_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.clml.2021.01.016","volume":"2","author":"K Bergin","year":"2021","unstructured":"Bergin K, et al. The myeloma landscape in Australia and New Zealand: the first 8 years of the myeloma and related diseases registry (MRDR). Clin Lymphoma Myeloma Leuk. 2021;2:2. https:\/\/doi.org\/10.1016\/j.clml.2021.01.016.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"17_CR31","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2217\/fon-2019-0013","volume":"15","author":"C Costello","year":"2019","unstructured":"Costello C, et al. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Futur Oncol. 2019;15(13):1411\u201328. https:\/\/doi.org\/10.2217\/fon-2019-0013.","journal-title":"Futur Oncol"},{"issue":"24","key":"17_CR32","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","volume":"128","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: A pharmacoeconomic perspective. Blood. 2016;128(24):2757\u201364. https:\/\/doi.org\/10.1182\/blood-2016-09-692947.","journal-title":"Blood"},{"issue":"1","key":"17_CR33","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1182\/BLOOD-2019-128769","volume":"134","author":"M Abu Haleeqa","year":"2019","unstructured":"Abu Haleeqa M, Alkaabi F, Janodi R, Raidullah E. First review of multiple myeloma patients in Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. Blood. 2019;134(1):5587. https:\/\/doi.org\/10.1182\/BLOOD-2019-128769.","journal-title":"Blood"},{"key":"17_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.564383","volume":"11","author":"A Ibrahim","year":"2021","unstructured":"Ibrahim A, Noun P, Khalil C, Taher A. Changing Management of Hematological Malignancies With COVID-19: statement and recommendations of the Lebanese society of hematology and blood transfusion. Front Oncol. 2021;11: 564383. https:\/\/doi.org\/10.3389\/FONC.2021.564383.","journal-title":"Front Oncol"},{"issue":"2","key":"17_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/joah.joah_62_18","volume":"10","author":"A Alaskar","year":"2019","unstructured":"Alaskar A, Alsaeed A, Alsharif F, Alhashmi H, Alghamdi M. Multiple myeloma in Saudi Arabia: consensus of the Saudi lymphoma\/myeloma group. J Appl Hematol. 2019;10(2):37. https:\/\/doi.org\/10.4103\/joah.joah_62_18.","journal-title":"J Appl Hematol"},{"issue":"10","key":"17_CR36","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1080\/10428194.2018.1427858","volume":"59","author":"D Tan","year":"2018","unstructured":"Tan D, et al. Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Leuk Lymphoma. 2018;59(10):2305\u201317. https:\/\/doi.org\/10.1080\/10428194.2018.1427858.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"17_CR37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","volume":"119","author":"B Paiva","year":"2012","unstructured":"Paiva B, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687\u201391. https:\/\/doi.org\/10.1182\/blood-2011-07-370460.","journal-title":"Blood"},{"issue":"15","key":"17_CR38","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15):1896\u2013906. https:\/\/doi.org\/10.1182\/blood-2015-08-665679.","journal-title":"Blood"},{"issue":"20","key":"17_CR39","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX study. J Clin Oncol. 2013;31(20):2540\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.46.2119.","journal-title":"J Clin Oncol"},{"issue":"25","key":"17_CR40","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: Results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975.","journal-title":"J Clin Oncol"},{"issue":"23","key":"17_CR41","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/BLOODADVANCES.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988\u201399. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020002827.","journal-title":"Blood Adv"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44228-022-00017-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44228-022-00017-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44228-022-00017-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:21:45Z","timestamp":1694424105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44228-022-00017-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17"],"URL":"https:\/\/doi.org\/10.1007\/s44228-022-00017-3","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"10 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI, NC, CH, WM, FN and AY have no conflicts of interests (financial\/other relationships) to declare. JEC declares receiving research support from Takeda. AB declares having the following financial\/other relationships: Speaker bureau or advisory board (Novartis, Roche, Sanofi, Jazz, Adienne, Astellas, Takeda, Hikma, Celgene, Jansen, MSD, Abbvie, Pfizer and Amgen); Research support (Roche, Takeda, Jansen, Astellas, Celgene, Pfizer and Amgen).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}